Building a Sustainable Future

Building a Sustainable Future

Thursday • May 4, 2023 • 2:00–5:30 PM CET • Auditorium Level 3
Co-Chairs: Stephen Stein, Kindeva Drug Delivery & David Lewis, Oz-UK Limited

followed by

Explore with Experts: The Sustainable Inhaler Challenge

A Sustainability Roadmap for Inhalation Products
Greg Anderson
Pharmacentric Solutions
Designing Inhalers for Reuse, Remanufacture and Recycling: Circularity in Medical Devices
Henry Blower and Dan Cowen
Cambridge Consultants
Accelerated Development of MDIs with Low GWP Propellants in a QbD Era: Practical, Regulatory and Scientific Considerations
Loy Britto
Healthy Airways
Optimizing Spray Formation in Solution and Suspension Low GWP Metered Dose Inhalers
Daniel Duke, Monash University and Benjamin Myatt, Kindeva Drug Delivery
Co-Suspension Aerosphere Technology Enabling the Pharmaceutical Transition to Non-HFA Pressurized Metered Dose Inhalers With Reduced Environmental Impact
David Lechuga
AstraZeneca
EXPLORE WITH EXPERTS
The Sustainable Inhaler Challenge
Co-Chairs: Stephen Stein, Kindeva Drug Delivery
and David Lewis, Oz-UK Limited

Discover More

Accelerating and De-Risking the Development of Low Global Warming Potential (GWP) pMDIs
Chris Baron, Lucas Silva and Jay Bhogaita
Aptar Pharma
HFO-1234ze(E): Adopting a Low-GWP Propellant for Metered Dose Inhalers
Erik Boldt, Laura Reinhard, Vidya Joshi and Kellisa Lachacz
Honeywell and AstraZeneca
Dry Powder Dosing of APIs: An Alternative Filling Technique for pMDIs
Sheryl Johnson and Johnathan Carr
Koura
PF
Leachables Assessment from a New Generation of pMDI Using Low Global Warming Potential Propellants
Jose Ferrao and Pauline Faucard
Aptar Pharma
GD
Filling and Dose Performance of pMDIs with New Low Global Warming Potential Propellants
Gerallt Williams and Gregoire Deraime
Aptar Pharma
KV
Drug Delivery Evaluation of AIRSUPRA™, a Fixed-Dose SABA/ICS Co-Suspension Delivery Technology Combination MDI
David Lechuga and Kou Vang
AstraZeneca
Quadruple Combination in a Pressurized Metered Dose Inhaler with Reduced Environmental Impact for the Treatment of COPD
David Lechuga
AstraZeneca
Comparative Aerosol Performance of an HFA-134a Based Fixed-Dose Triple Combination pMDI to One Made with HFO-1234ze - a Near-Zero Carbon Footprint Propellant
Kellisa Lachacz and David Lechuga
AstraZeneca
HFO-1234ze(E): Flammability Characterization for Metered Dose Inhaler Manufacturing
Gregory Smith
Honeywell
DROB
An Evaluation of Solution and Suspension pMDIs Containing HFA152a and HFO1234ze Using Clinically Relevant Test Methods
David Riley and Olivia Brittain
Kindeva Drug Delivery
JM
Anti-Microbial Properties of Low-GWP pMDI Propellant P-152a
James Murray
Koura
HFA152a MDI Design: Matching the In Vitro Performance of HFA227ea and HFA134a MDIs
David Lewis
Oz-UK Limited
Towards Pharmaceutical Equivalence: A Comparison of Three MDIs: HFA152a, HFA134a, and HFA227ea
David Lewis
Oz-UK Limited
Comparison of Spray Characteristics of P-134a and Low GWP P-152a pMDIs With and Without Ethanol
Lynn Jordan
Proveris Scientific Corporation
Albuterol Sulfate Metered Dose Inhaler Feasibility Using an Environment Friendly Propellant HFA152a and Novel Valves
Lei Mao
Recipharm
Comparison of Simulated pMDI Droplet Sizes of Fluticasone Propionate Suspension and Solution Formulations to Next Generation Impactor Data
Benjamin Thorne
Recipharm
AW
Evolving Strategies for Designing a Sustainable Inhaler
Prem-Sagar Tank and Alastair Willoughby
Team Consulting
Droplet Characteristics of Low Global Warming Potential Propellants at Different Ambient Humidities
Hui Wang
University of Alberta
A Roadmap for Constructing a Beclomethasone pMDI Solution Using HFA152a
Francesca Buttini
University of Parma
CO-ORGANIZERS
CONFERENCE SUPPORTERS
WORKSHOP PRESENTERS
EXHIBITORS

Exhibitors

↑ Back to Top